Latest News

STAT Plus: Zai Lab targets blood cancers in deal with Regeneron

Shanghai’s Zai Lab (ZLAB) is adding a blood cancer drug to its pipeline through a licensing deal with the U.S. biotech giant Regeneron (REGN).

Zai Lab will help develop and commercialize the bispecific antibody REGN1979 for the China, Hong Kong, Taiwan, and Macau market. Under the terms of the deal, the Chinese biotech is paying $30 million up front and potentially as much as another $160 million if the therapy meets certain regulatory and commercial milestones.

Continue to STAT Plus to read the full story…

Source link

Related posts

How Reading Books Can Help Curb Mental Health Problems


Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis


Prices Will Soon be Included in TV Drug Ads


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World